The Company has filed a prospectus supplement (the “Supplement”) dated
Copies of the Supplement and accompanying Base Prospectus may be obtained by contacting
BELLUS Health’s common shares are dual-listed on the Nasdaq and the
This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such province, state or jurisdiction.
About
Cautionary Note Regarding Forward-Looking Statements
Certain statements contained in this news release may constitute “forward-looking statements” within the meaning of applicable securities laws, including statements about sales of common shares pursuant to the Sales Agreement. Such statements, based as they are on the current expectations of management, inherently involve numerous important risks, uncertainties and assumptions, known and unknown. However, they should not be regarded as a representation that any of the plans will be achieved. Actual future events may differ from the anticipated events expressed in such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201223005559/en/
Director, Investor Relations and Communications
danny@bellushealth.com
Media:
Solebury Trout
jdeutsch@soleburytrout.com
Source: